MannKind

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. 

CEO
Michael E. Castagna
CEOMichael E. Castagna
Employees
407
Employees407
Headquarters
Danbury, Connecticut
HeadquartersDanbury, Connecticut
Founded
1991
Founded1991
Employees
407
Employees407

MNKD Key Statistics

Market cap
1.63B
Market cap1.63B
Price-Earnings ratio
50.41
Price-Earnings ratio50.41
Dividend yield
Dividend yield
Average volume
7.14M
Average volume7.14M
High today
$5.58
High today$5.58
Low today
$5.22
Low today$5.22
Open price
$5.45
Open price$5.45
Volume
4.29M
Volume4.29M
52 Week high
$7.63
52 Week high$7.63
52 Week low
$3.38
52 Week low$3.38

MNKD News

Simply Wall St 1d
MannKind Expands United Therapeutics Deal Can New Platform Revenues Transform Its Long-Term Story?

On August 24, 2025, United Therapeutics announced an amendment to its collaboration agreement with MannKind, broadening the partnership to cover an additional d...

MannKind Expands United Therapeutics Deal Can New Platform Revenues Transform Its Long-Term Story?
Simply Wall St 1d
MannKind Corporation Looks Just Right With A 53% Price Jump

MannKind Corporation ( ) shareholders would be excited to see that the share price has had a great month, posting a 53% gain and recovering from prior weakness....

MannKind Corporation Looks Just Right With A 53% Price Jump
TipRanks 2d
Positive TETON-2 Study Results Drive Buy Rating and Price Target Increase for MannKind

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on MannKind today and set a price target of $11.00. Elevate Your Investing Strategy: Take advanta...

Analyst ratings

100%

of 8 ratings
Buy
100%
Hold
0%
Sell
0%

More MNKD News

TipRanks 2d
MannKind price target raised to $11 from $9 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on MannKind (MNKD) to $11 from $9 and keeps a Buy rating on the shares. United Therapeutics (UTHR) announced that...

TipRanks 2d
MannKind’s Strategic Collaborations and Innovations Drive Buy Rating Amid Promising IPF Treatment Developments

Analyst Yun Zhong of Wedbush maintained a Buy rating on MannKind, retaining the price target of $11.00. Elevate Your Investing Strategy: Take advantage of TipRa...

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.